| Shareholder Alert: The Ademi Firm investigates whether Nevro Corp. is obtaining a Fair Price for its Public Shareholders |
MILWAUKEE , Feb. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. |
prnewswire.com |
2025-02-24 14:03:00 |
Czytaj oryginał (ang.) |
| Nevro (NVRO) Expected to Beat Earnings Estimates: Should You Buy? |
Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-12 13:06:37 |
Czytaj oryginał (ang.) |
| Globus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain? |
GMED is set to acquire all shares of Nevro in an all-cash transaction, unlocking new growth opportunities. |
zacks.com |
2025-02-11 11:15:24 |
Czytaj oryginał (ang.) |
| NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the. |
businesswire.com |
2025-02-10 14:11:00 |
Czytaj oryginał (ang.) |
| Nevro (NVRO) Upgraded to Buy: What Does It Mean for the Stock? |
Nevro (NVRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-02-07 15:01:21 |
Czytaj oryginał (ang.) |
| Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock? |
Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
zacks.com |
2025-02-07 07:46:30 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Nevro Corp. - NVRO |
NEW YORK , Feb. 6, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Nevro Corp. (NYSE: NVRO ), relating to the proposed merger with Globus Medical. |
prnewswire.com |
2025-02-06 18:10:00 |
Czytaj oryginał (ang.) |
| NVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Nevro Corp. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSE: NVRO) to Globus Medical for $5.85 per share is fair to Nevro shareholders. Halper Sadeh encourages Nevro shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Nevro and its board of directors viola. |
businesswire.com |
2025-02-06 13:14:00 |
Czytaj oryginał (ang.) |
| Shareholder Alert: Ademi & Fruchter LLP Investigates Whether Nevro Corp. Is Obtaining a Fair Price for Its Public Shareholders |
MILWAUKEE--(BUSINESS WIRE)--Ademi & Fruchter LLP is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Nevro stockholders will receive only $5.85 per share, representing a total equity value of app. |
businesswire.com |
2025-02-06 12:14:00 |
Czytaj oryginał (ang.) |
| Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients |
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million. |
globenewswire.com |
2025-02-06 11:30:00 |
Czytaj oryginał (ang.) |
| Here's Why you Should Add Nevro Stock to Your Portfolio Now |
NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 preliminary results amid a weak SCS market. |
zacks.com |
2025-01-23 14:01:11 |
Czytaj oryginał (ang.) |
| Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 |
REDWOOD CITY, Calif. , Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on January 7, 2025, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 21,026 shares of Nevro's common stock to 10 new non-executive employees to induce them to accept employment with Nevro. |
prnewswire.com |
2025-01-21 18:30:00 |
Czytaj oryginał (ang.) |
| Nevro Stock Falls Despite Q4 Sales Beat on Strong SCS Demand |
NVRO's preliminary fourth-quarter revenues showcase decline in worldwide and U.S. revenues. |
zacks.com |
2025-01-15 15:25:16 |
Czytaj oryginał (ang.) |
| Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results |
Cash, Cash Equivalents and Short-Term Investments Increased Approximately $15.5 million in the Fourth Quarter of 2024 REDWOOD CITY, Calif. , Jan. 13, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its preliminary, unaudited fourth-quarter and full-year 2024 revenue and other financial results. |
prnewswire.com |
2025-01-13 10:30:00 |
Czytaj oryginał (ang.) |
| What Makes Nevro (NVRO) a New Buy Stock |
Nevro (NVRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-12-24 15:01:12 |
Czytaj oryginał (ang.) |
| Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 |
REDWOOD CITY, Calif. , Dec. 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on December 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 26,000 shares of Nevro's common stock to 20 new non-executive employees to induce them to accept employment with Nevro. |
prnewswire.com |
2024-12-17 18:30:00 |
Czytaj oryginał (ang.) |
| Here's Why you Should Retain Nevro Stock in Your Portfolio Now |
NVRO's continued technological innovations and business diversification plans raise optimism about the stock. |
zacks.com |
2024-12-17 11:06:11 |
Czytaj oryginał (ang.) |
| Bet on 5 Top-Ranked Stocks With Rising P/E |
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Stryve Foods, Nevro, Canoo, MSA Safety and VTEX. |
zacks.com |
2024-12-10 10:05:40 |
Czytaj oryginał (ang.) |
| Nevro resumed with an Equal Weight at Wells Fargo |
Wells Fargo resumed coverage of Nevro with an Equal Weight rating and $5 price target. Wells believes Nevro is comfortable with consensus implying a return to year over year sales growth in the second half of 2025, though the firm does not see upside to Street estimates, the analyst tells investors in a research note. Easier y/y comps, lessened competitive trialing, AdaptivAI ramp, continued healthy growth in painful diabetic neuropathy, adding new sales territories, and Vyrsa ramping could support 2025 growth, the firm says. |
https://thefly.com |
2024-12-03 07:49:35 |
Czytaj oryginał (ang.) |
| Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos |
Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to “Attractive,” believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong. |
benzinga.com |
2024-12-02 16:29:58 |
Czytaj oryginał (ang.) |
| NVRO Stock Declines Despite Positive Study Data of Nevro1 System |
Nevro unveils publication of positive data study regarding its Nevro1 SI Joint Fusion System. |
zacks.com |
2024-11-19 12:30:40 |
Czytaj oryginał (ang.) |
| New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches |
Furthering Nevro's body of evidence as an innovation leader in pain management, da ta highlights the company's posterior integrated transfixation cage system REDWOOD CITY, Calif. , Nov. 18, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in Medical Devices: Evidence and Research , which demonstrate the superiority of the Nevro1™ SI Joint Fusion System ("Nevro1"), a posterior integrated transfixation cage system offering enhanced stability, minimized bone removal and increased fusion potential compared to a posterolateral cylindrical threaded single-implant system. |
prnewswire.com |
2024-11-18 10:30:00 |
Czytaj oryginał (ang.) |
| Nevro Stock May Gain on the CE Mark Certification for HFX iQ |
NVRO's HFX iQ SCS system receives CE Mark Certification in Europe. Nevro expects to begin launching HFX iQ in select European countries from the first quarter of 2025. |
zacks.com |
2024-11-15 11:30:21 |
Czytaj oryginał (ang.) |
| Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 |
REDWOOD CITY, Calif. , Nov. 15, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on November 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 37,726 shares of Nevro's common stock to 24 new non-executive employees to induce them to accept employment with Nevro. |
prnewswire.com |
2024-11-15 10:30:00 |
Czytaj oryginał (ang.) |
| Nevro Stock Rises on Q3 Earnings Beat, Revenues Decrease Y/Y |
NVRO's third-quarter earnings beat its Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level. |
zacks.com |
2024-11-12 14:05:14 |
Czytaj oryginał (ang.) |
| Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally |
HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence with cloud data insights, leading the way for personalized, data-driven patient care* REDWOOD CITY, Calif. , Nov. 12, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has received CE Mark Certification in Europe for its HFX iQ™ spinal cord stimulation (SCS) system. |
prnewswire.com |
2024-11-12 09:00:00 |
Czytaj oryginał (ang.) |
| Nevro Corp. (NVRO) Q3 2024 Earnings Call Transcript |
Nevro Corp. (NYSE:NVRO ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Angie McCabe - Vice President, Investor Relations & Corporate Communications Kevin Thornal - Chief Executive Officer & President Rod MacLeod - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Shagun Singh - RBC Capital Markets Robbie Marcus - JPMorgan Matt Taylor - Jefferies Brandon Vazquez - William Blair Bill Plovanic - Canaccord Suraj Kalia - Oppenheimer Richard Newitter - Truist Securities David Rescott - Baird Operator Good afternoon. My name is Krista, and I will be your conference operator today. |
seekingalpha.com |
2024-11-11 23:11:32 |
Czytaj oryginał (ang.) |
| Nevro (NVRO) Reports Q3 Loss, Tops Revenue Estimates |
Nevro (NVRO) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $0.65 per share a year ago. |
zacks.com |
2024-11-11 20:21:10 |
Czytaj oryginał (ang.) |
| Nevro Reports Third-Quarter 2024 Financial Results |
Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif. , Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. |
prnewswire.com |
2024-11-11 18:05:00 |
Czytaj oryginał (ang.) |
| New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy |
Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic Neuropathy and Type 2 Diabetes REDWOOD CITY, Calif. , Oct. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in the Journal of Pain Research demonstrating significant, durable pain relief and long-term and clinically meaningful reductions in hemoglobin A1c (HbA1c) and weight in study participants with painful diabetic neuropathy (PDN) and Type 2 diabetes who received 10 kHz high-frequency spinal cord stimulation (SCS) therapy.1 Globally, the number of people with diabetes has quadrupled in the last two decades2, and PDN impacts up to 25% of all people with diabetes.3 PDN can have significant impacts on the quality of life for people living with this condition, with symptoms like numbness, tingling/paresthesia, loss of protective sensation, impaired balance, and reduced response to sensory stimuli.4 Patients typically manage PDN with oral pain medications, but the efficacy of these medications is relatively low and can result in intolerable side effects.5 As a result, people with PDN suffer from significantly reduced health-related quality of life (HRQoL), impaired functionality and other comorbidities like sleep disorders, depression, and anxiety.6 The analysis evaluated 144 patients with Type 2 diabetes and refractory PDN who received 10 kHz SCS therapy during the SENZA-PDN randomized controlled trial (RCT), the largest RCT to evaluate SCS to treat PDN. |
prnewswire.com |
2024-10-29 18:30:00 |
Czytaj oryginał (ang.) |
| Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 |
REDWOOD CITY, Calif. , Oct. 16, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on October 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 26,088 shares of Nevro's common stock to five new non-executive employees to induce them to accept employment with Nevro. |
prnewswire.com |
2024-10-16 20:30:00 |
Czytaj oryginał (ang.) |
| Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024 |
REDWOOD CITY, Calif. , Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024. |
prnewswire.com |
2024-10-10 20:45:00 |
Czytaj oryginał (ang.) |
| Here's Why you Should Retain Nevro Stock in Your Portfolio Now |
Strength in NVRO's Senza Platform and business diversification plans raises optimism about the stock. |
zacks.com |
2024-09-26 17:50:18 |
Czytaj oryginał (ang.) |
| NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform |
Nevro announces the FDA approval and limited market release of HFX iQ with HFX AdaptivAI. |
zacks.com |
2024-09-25 16:46:18 |
Czytaj oryginał (ang.) |